Arcturus Therapeutics Holdings Inc. (ARCT)
- Previous Close
31.89 - Open
31.89 - Bid 31.64 x 100
- Ask 32.04 x 100
- Day's Range
30.76 - 31.95 - 52 Week Range
17.52 - 45.00 - Volume
163,618 - Avg. Volume
557,006 - Market Cap (intraday)
856.431M - Beta (5Y Monthly) 2.76
- PE Ratio (TTM)
-- - EPS (TTM)
-4.03 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
77.43
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
arcturusrx.comRecent News: ARCT
Performance Overview: ARCT
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARCT
Valuation Measures
Market Cap
858.86M
Enterprise Value
602.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.70
Price/Book (mrq)
3.25
Enterprise Value/Revenue
5.45
Enterprise Value/EBITDA
-25.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-86.16%
Return on Assets (ttm)
-17.22%
Return on Equity (ttm)
-36.17%
Revenue (ttm)
124.53M
Net Income Avi to Common (ttm)
-107.3M
Diluted EPS (ttm)
-4.03
Balance Sheet and Cash Flow
Total Cash (mrq)
288.4M
Total Debt/Equity (mrq)
12.09%
Levered Free Cash Flow (ttm)
-4.99M
Research Analysis: ARCT
Company Insights: ARCT
ARCT does not have Company Insights